RxDoctor Payments Data

Carmen Oakes

Family · Broken Arrow, OKNPI 1003040528

Payments from drug & device makers

$955in general payments, 2019–2025

Across 55 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$365
  • Astellas Pharma US Inc$109
  • AstraZeneca$87
  • Otsuka America Pharmaceutical, Inc.$66
  • Corium, LLC$63
  • Johnson & Johnson$44
  • plus $221 from 7 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$21,105
Medicare patients
123
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clonidine14$1,618
Levothyroxine Sodium83$815
Tamsulosin Hcl29$762
Escitalopram Oxalate49$726
Omeprazole68$673
Montelukast Sodium53$662
Atorvastatin Calcium47$604
Fluticasone Propionate18$466
Levetiracetam15$397
Potassium Chloride28$393
Meloxicam44$383
Imipramine Hcl14$321
Pravastatin Sodium26$303
Risperidone13$278
Metformin Hcl ErMetformin Hcl37$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$40$24921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →